Close Menu

NEW YORK – Takeda Pharmaceutical's mobocertinib has shown promising efficacy and safety in a Phase I/II trial in previously treated, advanced non-small cell lung cancer patients harboring EGFR exon 20 insertions. 

At the American Association for Cancer Research's Virtual Annual Meeting this week, Francois Gonzalvez, on behalf of Takeda, presented data showing that 43 percent of 28 mobocertinib-treated NSCLC patients with EGFR exon 20 insertions saw their tumors shrink and on average their tumors stopped progressing for around 7.3 months.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.